Summary
Vertex Pharmaceuticals Inc. reported a solid third quarter and first nine months of 2023, demonstrating continued revenue growth driven by its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO. Total product revenues reached $2.48 billion for the third quarter, an increase of 6% year-over-year, and $7.35 billion for the nine-month period, up 11%. Net income also saw a healthy increase, rising to $1.04 billion for the quarter and $2.65 billion for the nine months. The company is actively investing in its R&D pipeline, with significant increases in R&D and acquired in-process R&D expenses, reflecting progress in key therapeutic areas beyond CF, including sickle cell disease, beta-thalassemia, and various pain and kidney disease programs. Financially, Vertex maintains a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $13.6 billion as of September 30, 2023. The company also continues to execute its capital allocation strategy, evidenced by the $2.7 billion remaining authorization for share repurchases. Upcoming catalysts include regulatory decisions for exa-cel in sickle cell disease and beta-thalassemia, as well as anticipated results from pivotal clinical trials for vanzacaftor/tezacaftor/deutivacaftor in CF and VX-548 in acute pain, positioning the company for potential future growth.
Financial Highlights
48 data points| Revenue | $2.48B |
| Cost of Revenue | $318.70M |
| Gross Profit | $2.16B |
| SG&A Expenses | $263.80M |
| Operating Expenses | $1.45B |
| Operating Income | $1.04B |
| Net Income | $1.04B |
| EPS (Basic) | $4.01 |
| EPS (Diluted) | $3.97 |
| Shares Outstanding (Basic) | 258.00M |
| Shares Outstanding (Diluted) | 260.60M |
Key Highlights
- 1Product revenues increased by 6% to $2.48 billion in Q3 2023 and by 11% to $7.35 billion for the first nine months of 2023, primarily driven by TRIKAFTA/KAFTRIO.
- 2Net income grew to $1.04 billion in Q3 2023 (up 11% YoY) and $2.65 billion for the first nine months of 2023 (up 6% YoY).
- 3Research and Development (R&D) expenses significantly increased by 26% in Q3 and 27% for the nine-month period, reflecting investments in pipeline advancement.
- 4Acquired in-process R&D (AIPR&D) expenses surged by 78% in Q3 and 448% for the nine-month period, mainly due to significant upfront payments for collaborations and asset acquisitions.
- 5The company ended the period with a robust cash, cash equivalents, and marketable securities balance of $13.6 billion, up 25% from year-end 2022.
- 6Vertex is awaiting key regulatory decisions for exa-cel (SCD/TDT) with FDA action dates in December 2023 and March 2024.
- 7Pivotal clinical trial results for vanzacaftor/tezacaftor/deutivacaftor (CF) and VX-548 (acute pain) are expected in early 2024.